Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2003

View Archived Issues

New studies on atomoxetine presented at the APA meeting

TSU-68 active in patients with advanced solid tumors

CEP-701 reported to induce antitumoral effects in refractory AML

Good toxicity profile for CEP-7055 in patients with incurable solid tumors

Evidence of antitumor effects reported for ZD-6474 in refractory solid tumors

New PAF antagonists and their use as neuroprotectants described in recent patent

Pfizer claims novel protein kinase C inhibitors for use in pain, diabetic neuropathy, etc.

New antimicrobial carbapenems under study at Sumitomo

New factor Xa inhibitors, their preparation and use claimed by Kissei scientists

Maruha researchers identify new antagonists of Edg receptors

Novel EP2 receptor agonists with utility in glaucoma therapy discovered at Allergan

Schering-Plough researchers prepare and test new ORL-1 receptor agonists

New PPARgamma receptor modulators in Sankyo development pipeline

ImClone and BMS discuss Erbitux regulatory filing with FDA

GlaxoSmithKline advances development of GW-501516

Generex proposes acquisition of Antigen Express

Fujisawa and GSK sign U.S. copromotion agreement for Protopic

Ganymed and U. of Ghent come together for target validation

Roche's option to Vernalis A2A antagonist program in depression terminated

Dosing under way in phase II catheter occlusion trial of alfimeprase

Pivotal Actiza trial completes enrollment

Manufacturing of CoFactor underway

Enrollment completed in phase III alvimopan study in postoperative ileus

Nabi receives complete response for Nabi-HB

Medicure advances MC-4232 towards phase II/III

Grupo Vita signs marketing agreement for Eneas covering Turkey and Greece

Enrollment concluded in supportive phase III trial of Surfaxin for RDS

Phase III trial update on six-month Eligard product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 10, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026